S. pombe Genome-wide Heterozygous Deletion Mutant Screening Service (4,845 strains)
BIONEER's unique Drug Target & Toxicity Identification Services: GPScreen™
An Innovative Technology for Drug Target Identification using Drug-induced Haploinsufficiency (DIH) in the World's First Fission Yeast S. pombe Genome-wide Heterozygous Deletion Mutant Library
GPScreen™ Features and Benefits
The world's only innovative drug target identification technology based on S. pombe Genome-wide Deletion Mutant Library
Almost all types of drug targets possible to be screened at the genome level
Live cell-based screening
Fast and accurate high-throughput screening (HTS)
Applicable to drug repositioning, natural drug target discovery, drug toxicity evaluation
Drug target Identification and drug toxicity evaluation
Drug repositioning and drug efficacy improvement
Natural drug target discovery and mechanism of action (MOA) study
Accurate drug target identification is the first and the most crucial step for not only increasing the success rate for the new drug development, but also understanding the mode-of-actions, improving efficacy, tracing and avoiding side-effects. Bioneer has developed a new a high-throughput genome-wide drug target screening system called GPScreen™ and made it commercially available for researchers to be used for their drug discovery needs. This technology covers a broad spectrum of drug candidates in whole disease areas from cancers & metabolic diseases to neglected & rare diseases. This will ultimately provide the total solutions for an efficient drug discovery through providing clear-cut answers to problems such as drug-target(s) and toxicity as well as mode-of-actions of drug candidates.
GPScreen™ is based on S. pombe genome-wide deletion mutant library, developed together with Bioneer and the Korea Research Institute of Bioscience & Biotechnology (KRIBB) in collaboration with Dr. Paul Nurse of Cancer Research Center UK (Nat. Biotech, 28, 617–623, 2010). However, Bioneer has all the business' exclusive rights to this library and provides it for genetic and chemical screening such as drug target identification, gene expression profiling and synthetic lethal profiling.
The genomic library consists of a total of 4,845 gene variants and covers about 98.5% of the entire genome of the fission yeast S. pombe. Individual variants are those in which one of the pair of individual genes in normal cells is deficient by homologous recombination (Refer to image).
'Drug-induced Haploinsufficiency (DIH)' refers to the increased sensitivity of a heterozygous deletion mutant (a variant in which a specific protein is expressed to about half of a normal level) to a specific drug. This phenomenon occurs when a drug acts on a mutant in which a particular gene is missing and therefore, is considered to be a valuable tool for drug target identification. Previously, a number of reports have provided identifications of drug targets using DIH in the budding yeast S. cerevisiae (Baetz K et al., 2004; Lum et al., 2004). However, the fission yeast S. pombe is considered be a more ideal cell division model of mammalian cells since its cell cycle pattern is closer to that of mammalian cells (including human cells) than that of S. cerevisiae.
GPScreen™ technology can accurately define the drug targets at the genome level.
Figure 1. Drug Target Identification using GPScreen™
When a actin-binding inhibitor cytochalasin A (Fig. 1A) was treated to the S. pombe heterozygous deletion mutant library, a act1 gene deleted mutant showed more potent growth inhibition by the agent compared to those of other mutants, demonstrating that a human actin homologue gene act1 could play a role as a target of cytochalasin A in the S. pombe genome (Fig. 1B)